Company intelligence / Profile preview

PrimeVax Immuno-Oncology

Orange, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

PV001-DV has been tested in 21 healthy volunteers, demonstrating safety and powerful immune stimulation. Strong anti-tumor mechanisms have been repeatedly demonstrated in laboratory settings, with matching immune stimulation across healthy humans and cancer patient blood samples[1].

Therapeutic areas: OtherOncology
Modalities: Oncolytic virotherapyDendritic cell therapy
Industry: Biotech

Drug pipeline

2 assets

Autologous monocyte-derived lysate-pulsed dendritic cell vaccine PV-001-DC

1 more asset in the full pipeline.

Request access →

Partnerships

U.S. Army (exclusive license for DENV-1 45AZ5)

Beyond the preview

Go deeper on PrimeVax Immuno-Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PrimeVax Immuno-Oncology.

Explore the full profile